FourThought Financial Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

FourThought Financial Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-529	Closed	-$336K	–	332
2025 Q1	$336K	Sell	529 -82	-13%	-$56.4K	0.04%	229
2024 Q4	$435K	Buy	+611	New	+$513K	0.05%	200
2024 Q2	–	Sell	-688	Closed	-$662K	–	296
2024 Q1	$662K	Sell	688 -18	-3%	-$17.1K	0.08%	168
2023 Q4	$620K	Sell	706 -12	-2%	-$9.88K	0.08%	171
2023 Q3	$591K	Sell	718 -13	-2%	-$10.2K	0.08%	164
2023 Q2	$525K	Sell	731 -53	-7%	-$40.9K	0.07%	185
2023 Q1	$644K	Sell	784 -12	-2%	-$9.05K	0.09%	158
2022 Q4	$574K	Buy	+796	New	+$587K	0.08%	174

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FourThought Financial Partners's REGN Position: Q2 2025 in Review

FourThought Financial Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 529 shares — an estimated $336K sold.

FourThought Financial Partners first reported a position in REGN in Q4 2022 and held it in 8 quarters. The position peaked at $662K in Q1 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

FourThought Financial Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
FourThought Financial Partners sold 529 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $336K.
FourThought Financial Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 8 quarters.
FourThought Financial Partners's Regeneron Pharmaceuticals position peaked at $662K in Q1 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on FourThought Financial Partners's 13F filing for Q2 2025, filed 12 Aug 2025.